{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:29:59Z","timestamp":1793320199936,"version":"4.5.0"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T00:00:00Z","timestamp":1685059200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,9,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Streptococcus pyogenes (Strep A) infections result in a vastly underestimated burden of acute and chronic disease globally. The Strep A Vaccine Global Consortium\u2019s (SAVAC\u2019s) mission is to accelerate the development of safe, effective, and affordable S. pyogenes vaccines. The safety of vaccine recipients is of paramount importance. A single S. pyogenes vaccine clinical trial conducted in the 1960s raised important safety concerns. A SAVAC Safety Working Group was established to review the safety assessment methodology and results of more recent early-phase clinical trials and to consider future challenges for vaccine safety assessments across all phases of vaccine development. No clinical or biological safety signals were detected in any of these early-phase trials in the modern era. Improvements in vaccine safety assessments need further consideration, particularly for pediatric clinical trials, large-scale efficacy trials, and preparation for post-marketing pharmacovigilance.<\/jats:p>","DOI":"10.1093\/cid\/ciad311","type":"journal-article","created":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T10:24:56Z","timestamp":1685096696000},"page":"917-924","source":"Crossref","is-referenced-by-count":14,"title":["Safety of <i>Streptococcus pyogenes<\/i> Vaccines: Anticipating and Overcoming Challenges for Clinical Trials and Post-Marketing Monitoring"],"prefix":"10.1093","volume":"77","author":[{"given":"Edwin J","family":"Asturias","sequence":"first","affiliation":[{"name":"Colorado School of Public Health, University of Colorado , Aurora Colorado , USA"},{"name":"Children\u2019s Hospital, Anschutz Medical Campus, University of Colorado School of Medicine , Aurora, Colorado , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6462-5101","authenticated-orcid":false,"given":"Jean-Louis","family":"Excler","sequence":"additional","affiliation":[{"name":"Director General\u2019s Office, International Vaccine Institute , Seoul , Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Ackland","sequence":"additional","affiliation":[{"name":"Global BioSolutions , Melbourne , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Cavaleri","sequence":"additional","affiliation":[{"name":"Anti-Infectives and Vaccines, European Medicines Agency , Amsterdam , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alma","family":"Fulurija","sequence":"additional","affiliation":[{"name":"Group A Streptococcal and Rheumatic Heart Disease Team, Telethon Kids Institute , Perth , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj","family":"Long","sequence":"additional","affiliation":[{"name":"Safety and pharmacovigilance, Bill & Melinda Gates Foundation , London , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mignon","family":"McCulloch","sequence":"additional","affiliation":[{"name":"Department of Paediatrics, Red Cross War Memorial Children's Hospital, University of Cape Town , Cape Town , South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiranee","family":"Sriskandan","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Imperial College , London , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wellington","family":"Sun","sequence":"additional","affiliation":[{"name":"Vaxcellerant LLC , Silver Spring Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3961-2760","authenticated-orcid":false,"given":"Liesl","family":"Z\u00fchlke","sequence":"additional","affiliation":[{"name":"South African Medical Research Council, Parowvallei , Cape Town , South Africa"},{"name":"Division of Paediatric Cardiology, Department of Paediatrics, Institute of Child Health, Faculty of Health Sciences, University of Cape Town , Cape Town , South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome H","family":"Kim","sequence":"additional","affiliation":[{"name":"Director General\u2019s Office, International Vaccine Institute , Seoul , Republic of Korea"},{"name":"College of Natural Sciences, Seoul National University , Seoul , Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James B","family":"Dale","sequence":"additional","affiliation":[{"name":"College of Medicine, University of Tennessee Health Science Center , Memphis Tennessee , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew C","family":"Steer","sequence":"additional","affiliation":[{"name":"Infection and Immunity Theme, Tropical Diseases Research Group, Murdoch Children's Research Institute , Parkville Victoria , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,5,26]]},"reference":[{"key":"2023100601374837700_ciad311-B1","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1093\/cid\/ciac291","article-title":"A systematic framework for prioritizing burden of disease data required for vaccine development and implementation: the case for group A streptococcal diseases","volume":"75","author":"Moore","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2023100601374837700_ciad311-B2","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101458","article-title":"The global burden of sore throat and group A Streptococcus pharyngitis: a systematic review and meta-analysis","volume":"48","author":"Miller","year":"2022","journal-title":"EClinicalMedicine"},{"key":"2023100601374837700_ciad311-B3","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1093\/cid\/ciy1143","article-title":"The path to group A Streptococcus vaccines: World Health Organization research and development technology roadmap and preferred product characteristics","volume":"69","author":"Vekemans","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2023100601374837700_ciad311-B4","author":"Excler"},{"key":"2023100601374837700_ciad311-B5","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102740","article-title":"Rheumatic heart disease: a review of the current status of global research activity","volume":"20","author":"Dooley","year":"2021","journal-title":"Autoimmun Rev"},{"key":"2023100601374837700_ciad311-B6","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1093\/cid\/ciz425","article-title":"The limitations of the rheumatogenic concept for group A Streptococcus: systematic review and genetic analysis","volume":"70","author":"de Crombrugghe","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2023100601374837700_ciad311-B7","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1128\/CMR.13.3.470","article-title":"Pathogenesis of group A streptococcal infections","volume":"13","author":"Cunningham","year":"2000","journal-title":"Clin Microbiol Rev"},{"key":"2023100601374837700_ciad311-B8","doi-asserted-by":"crossref","DOI":"10.1128\/microbiolspec.GPP3-0045-2018","article-title":"Molecular mimicry, autoimmunity, and infection: the cross-reactive antigens of group A streptococci and their sequelae","volume":"7","author":"Cunningham","year":"2019","journal-title":"Microbiol Spectr"},{"key":"2023100601374837700_ciad311-B9","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.chom.2014.05.009","article-title":"The classical Lancefield antigen of group A Streptococcus is a virulence determinant with implications for vaccine design","volume":"15","author":"van Sorge","year":"2014","journal-title":"Cell Host Microbe"},{"key":"2023100601374837700_ciad311-B10","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1093\/infdis\/162.4.875","article-title":"A new heart-cross-reactive antigen in Streptococcus pyogenes is not M protein","volume":"162","author":"Barnett","year":"1990","journal-title":"J Infect Dis"},{"key":"2023100601374837700_ciad311-B11","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1128\/iai.62.6.2440-2449.1994","article-title":"Cloning and sequence analysis of a gene encoding a 67-kilodalton myosin-cross-reactive antigen of Streptococcus pyogenes reveals its similarity with class II major histocompatibility antigens","volume":"62","author":"Kil","year":"1994","journal-title":"Infect Immun"},{"key":"2023100601374837700_ciad311-B12","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1128\/am.16.3.509-518.1968","article-title":"Secondary and apparent primary antibody responses after group A streptococcal vaccination of 21 children","volume":"16","author":"Massell","year":"1968","journal-title":"Appl Microbiol"},{"key":"2023100601374837700_ciad311-B13","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1001\/jama.1969.03150190037007","article-title":"Rheumatic fever following streptococcal vaccination. Report of three cases","volume":"207","author":"Massell","year":"1969","journal-title":"JAMA"},{"key":"2023100601374837700_ciad311-B14","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1128\/JCM.40.5.1805-1810.2002","article-title":"Molecular analysis of group A Streptococcus type emm18 isolates temporally associated with acute rheumatic fever outbreaks in Salt Lake City, Utah","volume":"40","author":"Smoot","year":"2002","journal-title":"J Clin Microbiol"},{"key":"2023100601374837700_ciad311-B15","author":"US Food and Drug Administration"},{"key":"2023100601374837700_ciad311-B16","author":"US Food and Drug Administration","year":"2005"},{"key":"2023100601374837700_ciad311-B17","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41541-023-00609-x","article-title":"The Streptococcus pyogenes vaccine landscape","volume":"8","author":"Walkinshaw","year":"2023","journal-title":"NPJ Vaccines"},{"key":"2023100601374837700_ciad311-B18","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1001\/jama.292.6.709","article-title":"Safety and immunogenicity of a recombinant multivalent group A streptococcal vaccine in healthy adults: phase 1 trial","volume":"292","author":"Kotloff","year":"2004","journal-title":"JAMA"},{"key":"2023100601374837700_ciad311-B19","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1086\/444458","article-title":"Safety and immunogenicity of 26-valent group A Streptococcus vaccine in healthy adult volunteers","volume":"41","author":"McNeil","year":"2005","journal-title":"Clin Infect Dis"},{"key":"2023100601374837700_ciad311-B20","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.ics.2005.12.002","article-title":"A double-blind, randomized, phase II trial of the safety and immunogenicity of 26-valent group A Streptococcus vaccine in healthy adults","volume":"1289","author":"McNeil","year":"2005","journal-title":"Int Congr Ser"},{"key":"2023100601374837700_ciad311-B21","doi-asserted-by":"crossref","first-page":"8175","DOI":"10.1016\/j.vaccine.2011.09.005","article-title":"New 30-valent M protein-based vaccine evokes cross-opsonic antibodies against non-vaccine serotypes of group A streptococci","volume":"29","author":"Dale","year":"2011","journal-title":"Vaccine"},{"key":"2023100601374837700_ciad311-B22","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1016\/j.vaccine.2019.12.005","article-title":"Safety and immunogenicity of a 30-valent M protein-based group A streptococcal vaccine in healthy adult volunteers: a randomized, controlled phase I study","volume":"38","author":"Pastural","year":"2020","journal-title":"Vaccine"},{"key":"2023100601374837700_ciad311-B23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0198658","article-title":"Evaluation of safety and immunogenicity of a group A Streptococcus vaccine candidate (MJ8VAX) in a randomized clinical trial","volume":"13","author":"Sekuloski","year":"2018","journal-title":"PLoS One"},{"key":"2023100601374837700_ciad311-B24","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1177\/0192623310382559","article-title":"Use of tissue cross-reactivity studies in the development of antibody-based biopharmaceuticals: history, experience, methodology, and future directions","volume":"38","author":"Leach","year":"2010","journal-title":"Toxicol Pathol"},{"key":"2023100601374837700_ciad311-B25","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0140-6736(18)30999-1","article-title":"Acute rheumatic fever","volume":"392","author":"Karthikeyan","year":"2018","journal-title":"Lancet"},{"key":"2023100601374837700_ciad311-B26","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1161\/CIR.0000000000000205","article-title":"Revision of the Jones criteria for the diagnosis of acute rheumatic fever in the era of Doppler echocardiography: a scientific statement from the American Heart Association","volume":"131","author":"Gewitz","year":"2015","journal-title":"Circulation"},{"key":"2023100601374837700_ciad311-B27","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1093\/jpids\/piw070","article-title":"Prospective longitudinal analysis of immune responses in pediatric subjects after pharyngeal acquisition of group A streptococci","volume":"6","author":"Hysmith","year":"2017","journal-title":"J Pediatric Infect Dis Soc"},{"key":"2023100601374837700_ciad311-B28","volume-title":"Streptococcus pyogenes: basic biology to clinical manifestations [Internet]","author":"Martin","year":"2022","edition":"2nd ed"},{"key":"2023100601374837700_ciad311-B29","author":"European Medicines Agency"},{"key":"2023100601374837700_ciad311-B30","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1007\/s40264-020-00984-7","article-title":"Benefit-risk assessment of vaccines. Part I: a systematic review to identify and describe studies about quantitative benefit-risk models applied to vaccines","volume":"43","author":"Arlegui","year":"2020","journal-title":"Drug Saf"},{"key":"2023100601374837700_ciad311-B31","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1007\/s40264-020-00982-9","article-title":"Benefit-risk assessment of vaccines. Part II: proposal towards consolidated standards of reporting quantitative benefit-risk models applied to vaccines (BRIVAC)","volume":"43","author":"Arlegui","year":"2020","journal-title":"Drug Saf"},{"key":"2023100601374837700_ciad311-B32","author":"World Health Organization"},{"key":"2023100601374837700_ciad311-B33","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1161\/CIRCULATIONAHA.112.092312","article-title":"Echocardiography screening for rheumatic heart disease in Ugandan schoolchildren","volume":"125","author":"Beaton","year":"2012","journal-title":"Circulation"},{"key":"2023100601374837700_ciad311-B34","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/S0140-6736(11)61171-9","article-title":"Rheumatic heart disease","volume":"379","author":"Marijon","year":"2012","journal-title":"Lancet"},{"key":"2023100601374837700_ciad311-B35","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1056\/NEJMoa2102074","article-title":"Secondary antibiotic prophylaxis for latent rheumatic heart disease","volume":"386","author":"Beaton","year":"2022","journal-title":"N Engl J Med"},{"key":"2023100601374837700_ciad311-B36","doi-asserted-by":"crossref","first-page":"e5823","DOI":"10.1136\/bmj.e5823","article-title":"Use of population based background rates of disease to assess vaccine safety in childhood and mass immunisation in Denmark: nationwide population based cohort study","volume":"345","author":"Rasmussen","year":"2012","journal-title":"BMJ"},{"key":"2023100601374837700_ciad311-B37","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1080\/21645515.2017.1320007","article-title":"Background rates of disease in Latin American children from a rotavirus vaccine study","volume":"13","author":"Baay","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"2023100601374837700_ciad311-B38","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1097\/INF.0b013e318149dfea","article-title":"Human papilloma virus immunization in adolescent and young adults: a cohort study to illustrate what events might be mistaken for adverse reactions","volume":"26","author":"Siegrist","year":"2007","journal-title":"Pediatr Infect Dis J"},{"key":"2023100601374837700_ciad311-B39","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(09)61877-8","article-title":"Importance of background rates of disease in assessment of vaccine safety during mass immunisation with pandemic H1N1 influenza vaccines","volume":"374","author":"Black","year":"2009","journal-title":"Lancet"},{"key":"2023100601374837700_ciad311-B40","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1016\/j.vaccine.2021.03.016","article-title":"The critical role of background rates of possible adverse events in the assessment of COVID-19 vaccine safety","volume":"39","author":"Black","year":"2021","journal-title":"Vaccine"},{"key":"2023100601374837700_ciad311-B41","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1056\/NEJMoa1603693","article-title":"Global, regional, and national burden of rheumatic heart disease, 1990\u20132015","volume":"377","author":"Watkins","year":"2017","journal-title":"N Engl J Med"},{"key":"2023100601374837700_ciad311-B42","doi-asserted-by":"crossref","first-page":"e1423","DOI":"10.1016\/S2214-109X(21)00288-6","article-title":"Incidence of acute rheumatic fever in northern and western Uganda: a prospective, population-based study","volume":"9","author":"Okello","year":"2021","journal-title":"Lancet Glob Health"},{"key":"2023100601374837700_ciad311-B43","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1093\/ofid\/ofac249","article-title":"Standardization of epidemiological surveillance of group A streptococcal impetigo","volume":"9","author":"Miller","year":"2022","journal-title":"Open Forum Infect Dis"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciad311\/50686662\/ciad311.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/77\/6\/917\/51906045\/ciad311.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/77\/6\/917\/51906045\/ciad311.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T01:39:13Z","timestamp":1696556353000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/77\/6\/917\/7180116"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,26]]},"references-count":43,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,5,26]]},"published-print":{"date-parts":[[2023,9,18]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciad311","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,9,15]]},"published":{"date-parts":[[2023,5,26]]}}}